Item 7.01 Regulation FD Disclosure.



Members of Humana Inc.'s (the "Company") senior management team are scheduled to
meet with investors and analysts at various times between January 9, 2023 and
January 13, 2023. During these meetings, the Company intends to address its
prospects and performance. The date and time of presentations to investors are
available via the Investor Relations calendar of events on the Company's website
at www.humana.com.

Full Year 2023 Individual Medicare Advantage Enrollment Projection



Based on annual election period (AEP) growth of approximately 500,000 members,
the Company is increasing its net membership growth estimate for its individual
Medicare Advantage products for the year ending December 31, 2023 ("FY 2023") to
'at least 625,000' members from the previous guidance of 'at least 500,000'
members. The membership estimate represents expected net membership gains of
13.6 percent over the year ended December 31, 2022 membership of approximately
4.6 million members, above the Company's expectation of high single-digit
industry growth.

The upward revision is attributable to higher sales volumes and favorable member retention.

Full Year 2023 Adjusted EPS Commentary

For FY 2023, the Company intends to reiterate its commitment to grow 2023 Adjusted earnings per common share ("Adjusted EPS") within its targeted long-term range of 11-15 percent from its expected 2022 Adjusted EPS of approximately $25.00. As communicated on the Company's third quarter 2022 earnings call on November 2, 2022, it expects the consensus estimate of approximately $27.90 (as of November 2, 2022) to be in line with its initial Adjusted EPS guidance.

The increased 2023 individual Medicare Advantage membership projection is not expected to have a material impact on FY2023 Adjusted EPS expectations.

Full Year 2022 Adjusted EPS Guidance



For the year ended December 31, 2022 ("FY 2022") the Company intends to reaffirm
its guidance of approximately $23.27 in diluted earnings per common share
("EPS"), or approximately $25.00 in Adjusted EPS. This guidance is consistent
with the guidance issued in Humana's press release dated November 2, 2022 and
reaffirmed on December 1, 2022.

The Company has included Adjusted EPS in this current report, a financial
measure that is not in accordance with Generally Accepted Accounting Principles
("GAAP"). Management believes that this measure, when presented in conjunction
with the comparable measure of GAAP EPS, is useful to both management and its
investors in analyzing the Company's ongoing business and operating performance.
Consequently, management uses Adjusted EPS as an indicator of the Company's
business performance, as well as for operational planning and decision-making
purposes. Adjusted EPS should be considered in addition to, but not as a
substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to
Adjusted EPS follows:


--------------------------------------------------------------------------------

                Diluted earnings per common share                             FY 2022 Guidance
GAAP                                                                                  approximately $23.27
Amortization of identifiable intangibles                                                              0.48
Put/call valuation adjustments associated with Company's                                     (0.10)
non-consolidating minority interest investments
Transaction and integration costs                                                             0.62
Change in fair market value of publicly-traded equity securities                              0.72
Charges associated with productivity initiatives related to the                               1.73

previously disclosed $1 billion value creation plan Net gain on the sale of KAH Hospice

                                                          (1.72)
Adjusted (non-GAAP) - FY 2022 projected

approximately $25.00





The Company plans to host a conference call and announce its financial results
for the fourth quarter and year ended December 31, 2022, as well as provide
detailed financial guidance for the year ending December 31, 2023, on Wednesday,
February 1, 2023.

Cautionary Statement

This Current Report on Form 8-K includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, generally
including the words or phrases like "expects," "believes," "anticipates,"
"intends," "likely will result," "estimates," "projects" or variations of such
words and similar expressions that are intended to identify such forward-looking
statements. These forward-looking statements are not guarantees of future
performance and are subject to risks, uncertainties, and assumptions, including,
among other things, information set forth in the "Risk Factors" section of the
Company's SEC filings.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses